Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Economic Times
The Economic Times
Business

Lupin arm to commercialise YUVEZZI eye drop across key European markets

New Delhi: Pharma major Lupin Ltd on Thursday said its wholly-owned arm VISUfarma BV has entered into an exclusive licensing agreement with Visus Therapeutics Inc to commercialise YUVEZZI, an ophthalmic product indicated for the treatment of loss of clear close-up vision in adults, in specified global markets.

The licensing pact with Visus Therapeutics Inc, a wholly-owned arm of Tenpoint Therapeutics Holding Ltd, provides VISUfarma exclusive rights to undertake regulatory activities, commercialisation, marketing, promotion, distribution and sale of YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, in the European Union, the UK, Switzerland, Norway and Iceland, Lupin said in a regulatory filing.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.